TY - JOUR AU - Hoa Tran AU - Toi Vo AU - Minh Nam Nguyen PY - 2021/02/08 Y2 - 2024/03/29 TI - High expression of DIMT1 correlates with poor prognosis and high risk of bone metastasis in breast cancer patients JF - Science and Technology Development Journal: Health Sciences JA - STDJHS VL - 1 IS - 2 SE - Original research DO - https://doi.org/10.32508/stdjhs.v1i2.444 UR - http://stdjhs.scienceandtechnology.com.vn/index.php/stdjhs/article/view/444 AB - Background: Breast cancer often metastasizes to the bone that is the big reservoir of available tissue contained within the human skeleton and the environmental conditions surrounding it. Once cancer cells have metastasized to bone, they are generally incurable and have devastating effects on patients. However, the underlying molecular mechanisms of cancer metastasis to bone are poorly understood. It is still not clear why some patients metastasize, others do not, and not all metastatic patients progress bone metastasis. So, there is a clinical need to investigate the biomarkers that could accurately identify early prognostic prediction for patients with bone metastasis. Methods: Clinical information and gene expression profiles from breast cancer patients were retrieved from GEO, including GSE2034 (n=286) and GSE2603 (n=82). Chi-square, Kaplan-Meier curves, and log-rank tests were performed in the R environment to evaluate the prognostic value of DIMT1. All statistical analyses were considered significant if a value of less than 0.05. Results: We found that breast cancer patients with high expression levels of DIMT1 had poor bone metastasis-free survival outcomes and suggested DIMT1 as an independent predictor of bone metastasis. Moreover, DIMT1 also helps to obtain greater insights into the heterogeneity of breast cancer patients with triple-negative. Conclusion: DIMT1 is a potential predictor in gaining insights into the heterogeneous landscape of bone metastatic. Moreover, by integrating into the molecular subtypes, DIMT1 can further subclassify patients into two risk groups, thereby enabling more informed therapeutic decisions and improved prognostics for breast cancer. Together, these findings indicate the general utility of DIMT1 as a biomarker in the age of personalized and precision medicine. ER -